Established leader in detection solutions
Kromek delivered a sound, well-managed, H1 performance given industry-wide supply chain and components difficulties and inflationary costs, whilst preserving a healthy cash balance. It reported increased activity in the key medical imaging segment, with three new strategic OEMs, plus the receipt of multi-million-dollar contracts in CBRN (chemical, biological, radiological, nuclear) segment.The six months to 31 October 2021 saw: revenue of £4.71m +2.9%YoY, with gross margin at 46.8% (FY21: 48.4%), adjusted EBITDA loss of £0.63m (H1 21: loss £0.87m), PBT loss (rptd.) reduced from £3.4m to £3.1m, and period-end cash was £10.2m. The net cash position remained positive at £3.5m (FY21: £7.4m).
Kromek is now in a strong position to meet additional medium-term demand for its imaging equipment solutions, and is confident of market estimates of 45%YoY FY22 revenue growth; we estimate £15.0m for the full year.
We retain our 26p fair value per share but note that the Redlen acquisition by Canon leaves Kromek as the only commercial independent source of CZT-based technology for imaging systems. The read-across from that deal points to an entirely different valuation, in the range of 65p-75p per share.
Kromek Group is a developer of radiation detectors based on cadmium zinc telluride, providing detection and characterization capabilities within the medical imaging, nuclear detection and security screening markets. Co. designs, develops and produces x-ray and gamma-ray imaging and radiation detection products.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.